George Lopez, Jesse Garcia and Al Madrigal are among the new additions to the one-night-only virtual table read of the 2007 ...

"Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic ...

Madrigal talked about this, his upcoming series I’m Dying Up Here and more. I didn’t realize until halfway through Shrimpin’ Ain’t Easy that you, more than most comics I’ve seen this ...

Madrigal, who turns 28 on March 5, signed a one-year, $1.35 million contract with the Mets earlier this offseason. He's coming off a 2024 season for the Chicago Cubs in which he slashed .221/.280 ...

The Mets signed Madrigal to a one-year deal back in January after he had been non-tendered by the Cubs. He’s never been much of a hitter, with just four home runs in 940 big league plate ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union <li /> Conditional marketing au ...